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Abstract
Heparan sulfate carries a wide range of biological activities, regulating blood coagulation, cell
differentiation, and inflammatory responses. The sulfation patterns of the polysaccharide are
essential for the biological activities. In this study, we report an enzymatic method for the
sulfation of multimilligram amounts of heparan sulfate with specific functions using immobilized
sulfotransferases combined with a 3′-phosphoadenosine 5′-phosphosulfate regeneration system.
By selecting appropriate enzymatic modification steps, an inactive precursor has been converted to
the heparan sulfate having three distinct biological activities, associated with binding to
antithrombin, fibroblast growth factor-2, and herpes simplex virus envelope glycoprotein D.
Because the recombinant sulfotransferases are expressed in bacteria, and the method uses a low
cost sulfo donor, it can be readily utilized to synthesize large quantities of anticoagulant heparin
drug or other biologically active heparan sulfates.
Heparan sulfate (HS)3 is a ubiquitous component of the cell surface and extracellular matrix.
It regulates a wide range of physiologic and pathophysiologic functions, including
embryonic development and blood coagulation and can facilitate viral infection (1, 2). HS
exerts its biological effects by interacting with the specific proteins involved in a given
process (3). HS is a highly charged polysaccharide consisting of 1←4-linked glucosamine
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and glucuronic/iduronic acid units that contain both N- and O-sulfo groups. Unique
saccharide sequences within HS determine the specificity of the binding of HS to its target
proteins (4). Heparin, a specialized form of HS, is a commonly used anticoagulant drug.
Thus, new methods for the synthesis of heparin and HS attract considerable interest for those
developing anticoagulant drugs having improved pharmacological effects.
Chemical synthesis has been the major route to obtain structurally defined heparin and HS
oligosaccharides (5). The most important example involves the structure antithrombin-
binding pentasaccharide. Asynthetic pentasaccharide, based on this structure, has been
marketed in the United States under the trade name Arixtra. Arixtra is a specific factor Xa
inhibitor that is used clinically to prevent venous thromboembolic incidents during surgery.
Unfortunately, the total synthesis of heparin and HS oligosaccharides, larger than
pentasaccharides, is extremely difficult. HS analogues with 14 saccharide units inhibit the
activity of thrombin, but these synthetic analogues are simplified hybrid molecules of HS
oligosaccharides and highly sulfated glucose units (6, 7) and are not the naturally occurring
structures. Although our laboratory and others continue to pursue the synthesis of heparin
and HS oligosac-charides (8), it has become clear that chemical synthesis alone is currently
incapable of generating most larger oligosaccharide structures. The application of HS
biosynthetic enzymes for generating large heparin and HS oligosaccharides with desired
biological activities offers a promising alternative approach.
Six classes of enzymes are involved in the HS biosynthesis. HS is initially synthesized as a
copolymer of D-glucuronic acid and GlcNAc through the action of D-glucuronyl and N-
acetyl-D-glucosaminyltransferase (9). Next, a series of modifications take place, including
N-deacetylation andN-sulfation (carried out byN-deacetylase/N-sulfotransferase) of the
glucosamine residue to form N-sulfoglucosamine (GlcNS), C5 epimerization of glucuronic
acid (carried out by epimerase) to form L-iduronic acid (IdoUA), 2-O-sulfation of IdoUA
(carried out by 2-O-sulfotransferase (2-OST)), 6-O-sulfation of glucosamine (carried out by
6-O-sulfotransferase (6-OST)), and 3-O-sulfation of glucosamine (carried out by 3-O-
sulfotransferase (3-OST)) (10). The reactions catalyzed by 2-OST, 6-OST, and 3-OST are
shown in Fig. 1A. The enzymes responsible for HS biosynthesis have been cloned and
expressed and were employed in the synthesis of HS polysaccharides. Kuberan and
Rosenberg (11–13) utilized these enzymes to synthesize the HS containing antithrombin
binding sites with anticoagulant activity. Although this approach demonstrated for the first
time the feasibility of enzymatic synthesis of HS, approximately 1 μg of product was
generated, making extensive structural characterization and biological studies impossible.
Recently, Lindahl and colleagues reported an alternative chemoenzymatic approach for the
synthesis of anticoagulant heparin from heparosan, the E. coli K5 capsular polysaccharide
(14). This method utilized the C5 epimerase to convert D-glucuronic acid to IdoUA,
followed by the chemical persulfation and finally selective desulfation. Although this
approach afforded approximately 5 g of a heparin-like polysaccharide with anticoagulant
activity, unnatural saccharide units, such as 3-O-sulfo- D-glucuronic acid, were present in
their product, suggesting a limitation in the selectivity of chemical sulfation/desulfation in
HS synthesis. Thus, developing an effective and highly selective approach for O-sulfation of
polysaccharides remains a challenge for the large scale synthesis of HS.
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In this work, we describe an enzymatic approach to synthesize HS polysaccharides. Only
two or three enzymatic steps are required for the synthesis of HS having three biological
activities (Fig. 1). Two major advances have permitted the large scale synthesis of HS. First,
large amounts of all the required HS sulfotransferases have been successfully expressed in
Escherichia coli. Second, a PAPS regeneration system, developed by Burkhart and
colleagues (15), has been coupled to the enzymatic synthesis reactions. We synthesized HS
having specific biological activities including anticoagulant heparin, herpes simplex virus
glycoproteinD(gD)-binding HS, and fibroblast growth factor 2 (FGF2)- binding HS. Each of
these products had activities comparable with the heparin and HS. Furthermore, the amount
of synthesized HS was sufficient to permit not only disaccharide analysis but also analysis
using 1H NMR spectroscopy, resulting in the determination of the product structure with a
high degree of confidence. The results from our study suggest that this is a general method
for the large scale synthesis of a wide range of HS with specific activity required. In
addition, this method provides a model system to better understand the biosynthesis of HS.
EXPERIMENTAL PROCEDURES
Preparation of Chemically Desulfated N-Sulfated Heparin (CDSNS Heparin)
Treatment of heparin with a dimethyl sulfoxide/methanol mixture (9:1, v/v) at 80 °C for 24
h resulted in nearly complete N,O-desulfation with <5% of the solvolytically resistant O-
sulfo groups remaining. Chemical N-sulfation with sulfur trioxide-pyridine afforded CDSNS
heparin, which was characterized by disaccharide analysis and 1H and two-dimensional
COSY NMR.
Expression and Purification of 2-OST and 6-OST
The catalytic domains of 2-OST of Chinese hamster ovary (Arg51–Asn356) and mouse 6-
OST-1 (His53–Trp401) were cloned into the pMAL-c2X vector (New England BioLabs)
using the BamHI and HindIII sites to generate maltose- binding protein (MBP)-2-OST and
MBP-6-OST fusion proteins. The full-length cDNAs of 2-OST and 6-OST-1 were gifts from
Dr. Rosenberg (Massachusetts Institute of Technology, Cambridge, MA) and Dr. Kimata
(Aichi University, Japan), respectively. Expression of 2-OST and 6-OST was achieved in
Rosetta-gami B (DE3) cells (Novagen) using a standard procedure. Briefly, cells containing
the plasmid expressing 2-OST or 6-OST were grown in LB medium supplemented with 2
mg/ml glucose, 15 μg/ml tetracycline, 15 μg/ml kenamycin, 35 μg/ml chloramphenicol, and
50 μg/ml carbenicillin at 37 °C. When the A600 reached 0.6–0.8, Isopropyl-β-D-
thiogalactopyranoside (1mM)was added, and the cells were shaken overnight at 22 °C. The
bacteria were harvested, and the proteins were purified by following a protocol from the
manufacturer (New England Biolabs). The purified proteins migrated at 75 kDa on 12%
SDS-PAGE with the purity greater than 80%.
Preparation of Immobilized HS Sulfotransferases
Dialyzed sulfotransferases (3 ml, 4 mg/ml) in phosphate-buffered saline buffer (3 mM KCl,
1.5 mM KH2PO4, 8 mM Na2HPO4, 138 mM NaCl, pH 7.2) were mixed with 1ml of
Aminolink® plus beads (Pierce) following a protocol from the manufacturer. Immobilized
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enzyme was washed with 50 mM MES, 1% Triton X-100, 1 mM MgCl2, and 1 mM MnCl2,
pH 7.0, and stored at 4 °C.
Measurement of Enzymatic Activities of Immobilized Proteins
To determine the activity of 3-OST-1 and 3-OST-3, HS from bovine kidney (ICN
Biomedicals) was used as a substrate; to determine the activity of 6-OST and 2-OST,
CDSNS heparin was used as a substrate. Immobilized proteins (100μl, ~300μg of
immobilized enzyme) with 100μg of substrate (HS for 3-OST and CDSNS heparin for 2-
OST or 6-OST) and 200 μM [35S]PAPS (1000 cpm/pmol) in 1 ml of 50 mM MES, pH 7.0,
1% Triton X-100, 1 mM MgCl2, and 1 mM MnCl2. After rotating at room temperature for 1
h, the supernatant was collected, and the beads were washed with 3 × 200 μl of 1 M NaCl in
25 mM MOPS (pH 7.0). The supernatant and washes were combined, diluted with 2ml of
water, and subjected to DEAE chromatography to determine the amount of [35S]HS product
used to determine the activities of the various HS O-STs.
PAPS Regeneration System
The reactions involved in the PAPS regeneration system are shown in Fig. 1B. N-terminal
His6-tagged AST-IV was expressed in E. coli and purified as described by Burkat and
colleagues (15) at a yield of ~50 mg/liter of bacterial culture. The fulllength cDNA of rabbit
AST-IV was a generous gift of Dr. Michael Duffel (University of Iowa) (16).
Modification of Polysaccharides
All enzymatic modifications, including those catalyzed by 2-OST, 6-OST, 3-OST-1, and 3-
OST-3 followed the same protocol. Briefly, 20 mg of purified AST-IV was incubated with
40 μM PAP and 1 mM PNPS in 20 ml of 50 mM MES, pH 7.0, 1% Triton X-100, 1 mM
MgCl2, and 1 mM MnCl2 at 25 °C for 15 min. The reaction mixture was mixed with 4 ml of
immobilized sulfotransferase, 2 mg of a polysaccharide substrate was added, and the
mixture was rotated at 25 °C for 24 h. The supernatant was recovered, and the
polysaccharide that bound to the beads was eluted by washing three times with 8ml of 1 M
NaCl in 25mM MOPS. Both the supernatant and wash were combined and the product was
precipitated by adding ethanol (3 volumes). After incubating overnight at 4 °C,
polysaccharide was recovered by centrifugation.
Estimation of the Modification Level
The completion of 2-OST modification was monitored by incubating 10 μg of
polysaccharide (2) with 20 μg of soluble 2-OST in the presence of 100 μM of [35S]PAPS at
37 °C for 30 min. In a control experiment, 10 μg of compound 1 replaced the previously
modified polysaccharide in the otherwise identical reaction mixture. By comparing the
amount of 35S incorporation, we could estimate the extent of the original 2-O-sulfation
reaction. For monitoring the completion of 6-OST, compound 1 or 2 was used as a substrate;
for 3-OST-1, compound 4 was used.
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Using [35S]PAPS as a Sulfate Donor
Antithrombin (AT)-binding and gD-binding experiments utilized 35S-labeled
polysaccharides prepared using [35S]PAPS. In a typical reaction, 2 mg of HS substrate was
incubated with 4 ml of beads with immobilized sulfotransferase (~12 mg of immobilized
enzyme) at 25 °C in 20 ml of 50mM MES, pH 7.0, 1% Triton X-100, 1 mM MgCl2, and 1
mM MnCl2, 200 μM [35S]PAPS (1000 cpm/pmol) for 1 h. The resultant polysaccharide was
recovered using DEAE chromatography.
Disaccharide Analysis
Synthesized polysaccharides (100 μg) were degraded by amixture of heparin lyases as
previously described (17) and desalted on BioGel P-2 column (0.5 × 200 cm) in 0.1 M
NH4HCO3. Disaccharides were analyzed by a C18 reversed phase column (0.45×25 cm;
Vydac) with UV 232 detection and identified by coelution with appropriate standards (18).
The overall recovery yield of the disaccharide analysis was estimated by using 2-O-
[35S]heparin (100,000 cpm/70 ng; compound 2) as an internal control.
NMR Analysis
Polysaccharide sample (1–2 mg)was dissolved in 0.5 ml of 2H2O(99.9%), freeze dried to
remove exchangeable protons, redissolved in 75 μl of 2H2O (100.00%), and transferred to a
Shigemi NMR microtubes. NMR spectra were referenced relative to the HO2H at 4.80 ppm,
and in COSY water was suppressed by presaturation of the HO2H resonance.
Determination of the Binding to AT and FGF2 Using Surface Plasmon Resonance
Spectroscopy (SPR)
Heparin and the synthesized polysaccharides were biotinylated following the published
procedure (19). A solution of the biotinylated polysaccharides (0.1 mg/ml) in Hepes (10
mM), 0.15 M NaCl, 3 mM EDTA, and 0.005% surfactant P20 (HBS-EP) was flowed over
the cells of the streptavidin chip at 5 μl/min. To determine the KD values, different
concentrations (25–1600 nM in HBS-EP buffer) of FGF2 andATwere individually injected
at 30μl/min (running buffer: HBS-EP). Kinetic injection was used, leading the protein to
flow for 180 s and dissociated for the next 180 s, and the surface was regenerated by a 60-s
injection of 30 μl of 2 M NaCl. Response units were monitored as a function of time to
afford sensorgrams. The SPR curves for FGF2 fit well at individual concentrations, but the
global fit suggested significant binding heterogeneity. Thus, the equilibrium response unit
RU(eq) values from the sensorgrams of FGF2 binding to polysaccharide-containing surfaces
were used to construct Scatchard plots, RU(eq)/C versus RU(eq), where C is the free protein
concentration, resulting in linear, first degree polynomial functions confirming the one-to-
one binding of FGF-polysaccharide and to estimate binding affinity. A two-state reaction
model was applied to the AT-polysaccharide interactions measured by SPR using curve
fitting to estimate the association and dissociation rate constants and affinity constant.
FGF2/FGFR1C-mediated Proliferation Assay
The BaF3 cells ectopically expressing FGFR1C have been previously described (20). The
BaF3-FGFR1c cells were maintained in RPMI 1640 medium (Sigma) supplemented with
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10% fetal bovine serum, 0.5 ng/ml interleukin (IL)-3 (PeproTech Inc., Rocky Hill, NJ),
2mML-glutamine, penicillin (50 IU/ml) and streptomycin (50 μg/ml), and 50 μM β-
mercaptoethanol. For mitogenic assays, BaF3 FGFR1c cells were washed three times with
RPMI 1640 medium to remove IL-3 and resuspended in the growth medium lacking IL-3.
About 30,000 cells were plated per well in a 96-well plate in medium containing 1μg/ml
heparin, compound 1, 2, 3, 4a, or 4b, and 2 nM FGF-2 (PeproTech) in a total volume of 200
μl. The cells were then incubated at 37 °C for 40 h. To each well, an additional 50 μl of
growth medium containing 1 μCi of [3H]thymidine was added. Cells were harvested after 4–
5 h by filtration through glass fiber paper. The incorporation of [3H]thymidine into the DNA
was determined by scintillation counting.
Determination of the Binding of Compounds 5–8 to AT
Approximately 1 × 105 cpm of 35S-labeled compound was incubated with 5 μg of
humanAT(Cutter Biological) in 50μl of binding buffer containing 10 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM Mn2+, 1 mM Mg2+, 1 mM Ca2+, 10 μM dextran sulfate, 0.0004%
Triton X-100, and 0.02% sodium azide for 30 min at room temperature. Concanavalin A-
Sepharose (Sigma; 50μl of 1:1 slurry) was then added, and the reaction was shaken at room
temperature for 1 h. The beads were then washed by 3 × 1 ml of binding buffer, and the
bound polysaccharide was eluted with 1 M NaCl.
Inhibition Effect of the Polysaccharides on the Activities of Factor Xa and Thrombin
Assays were based on two previous methods (21, 22). Briefly, factor Xa (Enzyme Research
Laboratories, South Bend, IN) and thrombin (Sigma) were diluted to 20 and 8 units/ml with
phosphate-buffered saline containing 1mg/ml bovine serum albumin, respectively. AT was
diluted with phosphate-buffered saline containing 1 mg/ml bovine serum albumin to give a
stock solution at the concentration of 27 μM. The chromogenic substrates, S-2765 (for factor
Xa assay) and S-2238 (for thrombin assay) were from Diapharma and made up at 1mM with
1 mg/ml Polybrene in water. The synthesized polysaccharide (compounds 5, 7, and 8) or
heparin was dissolved in a buffer containing 50 mM Tris-HCl, pH 8.4, 7.5 mM Na2EDTA,
175 mM NaCl at various concentrations (1–10,000 ng/ml). The reaction mixture, which
consisted of 25μl of AT stock solution and 25μl of the solution containing polysaccharide,
was incubated at 37 °C for 2 min. Factor Xa (25 μl) or thrombin (25 μl) was added. After
incubating 37 °C for 4 min, 25 μl of S-2765 or S-2238 was added. The absorbance of the
reaction mixture was measured at 405 nm continuously for 10 min. The absorbance values
were plotted against the reaction time. The absorbance of the reaction mixture was measured
at 405 nm continuously for 10 min. The initial reaction rates as a function of concentration
were used to calculate the IC50 values. The concentrations of the synthesized
polysaccharides were determined using Alcian blue as described by Bjornsson (23) and
quantitative disaccharide analysis as described above.
The Binding to Herpes Simplex Virus gD
The assay for determining binding of 35S-labeled polysaccharides (compounds 5 and 6) to
gD was carried out by an immunoprecipitation procedure using anti-gD monoclonal
antibody (DL6) (24).
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Development of an Efficient Enzymatic Synthesis of Sulfated Polysaccharides
Expression of HS Sulfotransferases in E. coli—Our goal is to develop an approach
to synthesize FGF-binding HS (compound 4, including 4a and 4b) AT-binding HS
(compound 5), and herpes simplex virus gD-binding HS (compound 6). Four enzymes,
including 2-OST, 6-OST, 3-OST-1, and 3-OST-3, were required for the syntheses of these
targets. We recently demonstrated that bacterial expressed 3-OST-1 and 3-OST-3 exhibit
substrate specificity and specific enzymatic activity comparable with those of their
counterparts expressed in insect cells (17, 25). Expression of the catalytic domains of 2-OST
and 6-OST was also achieved in relatively high yield by preparing a fusion protein with
MBP and 2-OST or 6-OST in Rosetta-gami B cells. Because 2-OST and 6-OST fusion
proteins were enzymatically active and highly soluble, we decided to retain the MBP
domain in the current study.
Immobilized Enzymes Are Reusable—2-OST, 6-OST, 3-OST-1, and 3-OST-3 were
immobilized on agarose to be reusable and to enhance the thermal stability. We incubated
immobilized enzymes with polysaccharide substrate and PAPS for 1 h at room temperature.
The sulfated polysaccharide product was separated from the immobilized enzyme by
washing the beads with 1MNaCl followed by centrifugation, making the immobilized
enzymes ready for the next synthetic cycle. The cycle was repeated 10 times, after which
each of the immobilized enzymes were assayed and showed >80% of their catalytic activity
(Fig. 2). We have also found that the immobilized enzymes also maintained>65% of their
catalytic activity after 2 months of storage at 8 °C (data not shown).
Introduction of PAPS Regeneration System—PAP inhibits sulfotransferase-
catalyzed reactions. A PAPS regeneration system can be used to convert PAP to PAPS by
relying on AST-IV to catalyze the transfer of the sulfo group from PNPS to PAP, as
illustrated in Fig. 1B (15). We observed that the PAPS regeneration system performed very
well with 2-OST, 6-OST, and 3-OST-1. Complete modification of the substrate could be
demonstrated by the low susceptibility of polysaccharide product to undergo additional
sulfation using [35S]PAPS with soluble enzymes, as described under “Experimental
Procedures.” Under the standard conditions, 2-OST, 6-OST, and 3-OST-1 afforded 98, 97,
and 98% complete modification, respectively, using the PAPS regeneration system. These
results demonstrate that the PAPS regeneration system functioned properly, providing
sufficient PAPS for the complete sulfotransferase- catalyzed modification of polysaccharide
substrates. This conclusion was further supported by characterizing the structures of the
newly synthesized polysaccharide products 2, 3, 4a, 4b, and 5 (described below). In a
parallel experiment, we used [35S]PAPS as the sulfo donor to sulfate the polysaccharides in
order to estimate the number of sulfo groups that were incorporated into the product. Six 2-
O-sulfo and 6-O-sulfo groups and three 3-O-sulfo groups were estimated to be transferred to
one polysaccharide molecule, respectively, assuming that the length of the polysaccharide is
25 disaccharide units. Approximately 1.5 mg of anticoagulant HS (5) was synthesized from
10 mg of CDSNS heparin (1) using immobilized sulfotransferases and the PAPS
regeneration system.
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Structural Characterization of Synthesized Polysaccharides
Disaccharide Analysis of the Polysaccharides—Synthesized polysaccharide
intermediates were digested with a mixture of heparin lyases, and the resulting disaccharides
were analyzed using RPIP-HPLC (Fig. 3). As expected, analysis of compound 1 showed a
disaccharide component of the structure of ΔUA-GlcNS (disaccharide 2), residual unsulfated
disaccharide, ΔUA-GlcNAc (disaccharide 1), and small amounts of sulfated disaccharides
(disaccharides 3–5) due to incomplete chemical desulfation (Fig. 3A and TABLE ONE). The
modification by 2-OST elevated the level of ΔUA2S-GlcNS (disaccharide 4) by about 5-fold
(Fig. 3B and TABLE ONE), confirming the structure of compound 2. Analysis of compound
3 afforded a 7-fold increase in the level of the disaccharide ΔUA-GlcNS6S (disaccharide 3)
compared with compound 1, consistent with 6-OST-catalyzed modification (Fig. 3C and
TABLE ONE). The level of trisulfodisaccharide, ΔUA2S-GlcNS6S (disaccharide 5), in
compounds 4a and 4b was increased by about 10-fold compared with that of compound 1
(Fig. 3, D and E, and TABLE ONE). The results from the disaccharide analysis clearly
establish that the expected enzymatic modifications took place at each step. It is interesting
to note that 6-O-sulfation occurs at N-sulfoglucosamine, consistent with the substrate
specificity of 6-OST in vitro (26). The 2-O-sulfation predominantly occurs at the uronic acid
with an N-sulfoglucosamine residue at the reducing end. We also note that substantial
amounts of ΔUA-GlcNS (disaccharide 2) remain in compounds 4a and 4b. This observation
is not unexpected, since the HS from various tissues also afford a ΔUA-GlcNS disaccharide
unit, suggesting that the structures of compounds 4a and 4b are similar to HS from natural
sources (27).
NMR Analysis of the Polysaccharides—The 1H NMR analysis was conducted on the
synthesized polysaccharides to allow us to assess their structures at the polymer levels as
well as to estimate the composition. The assignment of each nonexchangable proton was
made using COSY, and their chemical shifts are reported in TABLE TWO.
The integration of the N-acetyl signal in the 1H NMR of heparin was compared with the
integration of the GlcNS-H1 signal, allowing us to estimate the level of modifications. The
ratio of these integrals showed that ~15% of the glucosamine residues contained N-acetyl
groups. Using this information, we examined the incorporation of 2-O-, 3-O-, and 6-O-sulfo
groups. Comparison of the N-acetyl peak with IdoUA2S-H2 in compound 2 demonstrates
incorporation of a 2-O-sulfo group into 35% of the IdoUA residues. Based on this
incorporation into compound 2, the integral of GlcNS-H6a and IdoUA2S-H2 (overlapping
signal) was compared with the integral of the N-acetyl methyl group in compound 4a to
estimate the level of incorporation of the 6-O-sulfo group. Integration showed that the 6-O-
sulfo group was incorporated into 25% of the GlcNS residues. The reduced level of
incorporation is not surprising, since only the 6-OST-1, and not 6-OST-2 and -3, was used in
this synthesis. In compound 5, the incorporation of the 3-O-sulfo group was calculated by
comparing the integral of the N-acetyl methyl group with GlcN-H3 and IdoUA-H4
(overlapping signal). Based on these calculations, the 3-O-sulfo group was incorporated into
32% of the GlcNS6S residues. According to 1HNMR and COSY experiments (TABLE
TWO), the structures of the compounds 4a, 4b, and 5 were all found to be similar to heparin
and contained no unusual signals. Compound 5 showed a slightly greater heterogeneity, as
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evidenced by additional minor signals corresponding to additional 3-O-sulfo group-
containing sequences in the 1H NMR, when compared with heparin. This is not unexpected,
since heparin contains a lower level of 3-O-sulfo groups/chain than the content of 3-O-sulfo
groups/chain observed in compound 5 as determined by 35S incorporation.
The composition estimated by NMR is consistent with the results of disaccharide analysis.
NMR analysis suggests that about 15% of the glucosamine unit is N-acetylated, which is
similar to the results of disaccharide analysis for ΔUA-GlcNAc (14–22%; TABLE ONE).
NMR analysis demonstrates that compound 2 consists of 35% of IdoUA2S-GlcNS, and
compound 4a consists of 25% of IdoUA2S-GlcNS6S, and disaccharide analysis
demonstrates that compounds 2 and 4a contain 40% of ΔUA2S-GlcNS and 30% of ΔUA2S-
GlcNS6S, respectively. Because of the signal overlap, we were unable to calculate the
degree of 6-O-sulfation in compounds 3 and 4b using 1HNMR.
Determination of the Biological Activities of the Synthesized Polysaccharides
The Binding of the Polysaccharides to AT and FGF2—Characterization of the
affinities of AT to heparin and enzymatically modified heparin derivatives were performed
by SPR. A two-state reaction model was applied to the SPR study of AT and polysaccharide
interactions using BIA evaluation Software for curve fitting analysis. None of the
derivatives with the exception of the 2,6,3-O-sulfopolysaccharide (5) and heparin had high
affinity to AT. The binding constant (KD) for the binding of compound 5 to AT was
determined to be 170 nM, which is very similar to that of heparin (75 nM).We also
estimated the binding affinity of FGF2 to the synthesized polysaccharides. Compound 1
showed no interaction with FGF2, whereas compounds 4a and 4b showed the identical
binding affinity to FGF2 at a Kd of 35 nM, which is similar to heparin (22 nM) and is
consistent with the value reported in the literature (28).
Synthetic Polysaccharides Promote Cell Proliferation—The BaF3 FGFR1c cells
normally depend on IL-3 for growth. In the absence of IL-3, the cell proliferation depends
on the addition of both FGF and heparin or HS (20). We measured the activity of
compounds 1, 2, 3, 4a, and 4b and heparin in promoting cell mitogenesis using the FGF-2/
FGFR1c system in BaF3 cells as described under “Experimental Procedures.” The cells
receiving compounds 4a and 4b (at 1 μg/ml) showed an increase in [3H]thymidine
incorporation, which was about 60 and 40% of that of heparin, respectively, suggesting that
the combinations of 2-O- and 6-O-sulfations confer the activity in promoting cell
proliferation (Fig. 4A). We also compared the activity of 4a and 4b with that of heparin at
different concentrations (Fig. 4B). We found that compound 3 had moderate activity in
promoting cell proliferation, whereas compounds 1 and 2 did not exhibit activity. The results
are consistent with previously reported data on the contributions of the sulfo groups of HS to
the mitogenic activity (29, 30). We noted that 4a appears to have stronger activity in
promoting cell proliferation than 4b, suggesting that different sequences are generated by
the different order of 2-O- and 6-O- sulfation as suggested by Jacobsson and Lindahl (31).
However, such sequence difference could not be detected by the disaccharide or NMR
analysis.
Chen et al. Page 9






















The Anticoagulant Activity of the Synthesized Polysaccharides—Heparin
achieves its anticoagulant activity by forming a 1:1 complex with AT, which inhibits the
activities of factor Xa and thrombin (32). Because it is known that the introduction of the 3-
O-sulfo group by 3-OST-1 is essential for the synthesis of anticoagulant HS, we prepared
different types of 3-O-sulfo group-containing polysaccharides, compounds 5, 7, and 8, and
tested their activities in inhibiting factor Xa and thrombin (TABLE THREE). As expected,
heparin is a potent activator for AT-mediated inhibition of factor Xa and thrombin, whereas
Arixtra specifically activates the AT-mediated inhibition of factor Xa (5). Compound 5 has
very similar potency to heparin, inhibiting the activities of both factor Xa and thrombin,
suggesting that our enzyme-based approach is indeed capable of synthesizing the
anticoagulant polysaccharide. It has been reported that the presence of 2-O-sulfo groups is
not essential for HS binding to AT and its resulting anticoagulant activity (33). Indeed, our
polysaccharide intermediate compound 8 lacks 2-O-sulfo groups but still exhibits
anticoagulant activity, consistent with this previous report (33). In contrast, compound 7
lacks 6-O-sulfo groups and, thus, has no anticoagulant activity, since 6-O-sulfo groups are
critical in AT binding (34). Another 3-O-sulfated polysaccharide (compound 6) was also
prepared to test for its anti-Xa and antithrombin activities. It is important to note that both
compounds 5 and 6 carry a 3-O-sulfoglucosamine unit, although it is located in different
saccharide sequences (Fig. 1A). It is known that 3-OST-3-modified HS does not bind to AT
(35). As expected, compound 6 does not exhibit any anti-Xa and antithrombin activities. We
also measured the binding of AT to the synthesized compounds (TABLE THREE). It is
clear that the anticoagulant activities of the compounds correlated to their binding affinity to
AT. Taken together, these results demonstrate that the anticoagulant activities of these
enzymatically synthesized polysaccharides are consistent with the known structure activity
relationship of HS.
Preparation of the Polysaccharide That Binds to Herpes Simplex Virus gD—
Herpes simplex virus utilizes HS as a receptor to infect the target cells (36). A specific 3-O-
sulfo group-containing HS, generated by 3-OST-3, -5, or -6, serves as an entry receptor for
herpes simplex virus type 1 through HS binding of gD (24, 37, 38). Structural
characterization of the gD-binding site revealed a unique octasaccharide sequence carrying a
3-O-sulfo glucosamine residue (39). To test if our enzymatic approach synthesizes gD-
binding HS, we incubated compound 4 with immobilized 3-OST-3 to generate compound 6.
We have found that 12% of the resultant polysaccharide (compound 6) bound to gD,
whereas only 2.6% of compound 5, a 3-OST-1-modified polysaccharide, bound to gD as
determined by immunoprecipitation (TABLE FOUR). Comparison with the appropriate
controls showed that the percentage binding for 3-OST-3-modified HS closely resembled
that of compound 6. In conclusion, our results suggest that our enzymatic approach is
capable of effectively synthesizing gD-specific binding HS. It should be noted that
commercial heparin does not bind to gD, and heparin is not a substrate for 3-OST-3 (40, 41).
Therefore, our results also demonstrate that it is possible to redesign the sulfation patterns by
first solvolytically removing all O-sulfo groups and then selectively enzymatically replacing
sulfo groups required for specific interactions.
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Heparin and HS have a wide range of biological activities, including anticoagulation,
antiviral, and anticancer activities. Sulfo group-containing saccharide sequences dominate
the specificity of the functions of heparin and HS. Thus, the synthesis of a polysaccharide
with the appropriate positioning of these critical functional groups to carry out its unique
biological activity represents an important goal. In this study, we report an approach to
synthesize sulfo group-containing HS polysaccharides that bind to FGF2, herpes simplex
virus gD, and AT. These HS polysaccharides can also demonstrate appropriate biological
activity, such as anticoagulant activity mediated through AT binding and the activity in
promoting cell proliferation. More importantly, this approach permits the synthesis of
greater than 1mg amounts of specific sulfo group-containing polysaccharides, sufficient for
testing their activities in biochemical and biological assays. The quantities synthesized are
also sufficient for extensive structural analysis, including disaccharide analysis and one- and
two-dimensional NMR analysis.
Two approaches were used to increase the scale of enzymatic synthesis. First, HS
sulfotransferases were expressed in E. coli, readily affording 20–50 mg of purified enzymes.
We had previously shown that both 3-OST-1 and 3-OST-3 were expressed in E. coli in
relatively high yield. In this study, both 2-OST and 6-OST were similarly expressed in E.
coli as the soluble 2-OST and 6-OST-MBP fusion proteins. Second, we improved efficiency
of enzymatic sulfation by utilizing immobilized O-sulfotransferases and coupling their use
to a PAPS regeneration system. When this PAPS regeneration system was applied for
preparing N-sulfoheparosan from heparosan using N-deacetylase/N-sulfotransferase, the N-
sulfation yield was lower than that obtained using added exogenous PAPS (42). We
considered the application of this system essential to our study for the following reasons.
First, PAP inhibits HS O-sulfotransferase activities with IC50 values of ~100 μM under the
reaction conditions used in our syntheses (data not shown), making milligram-scale
synthesis difficult without continuously removing PAP. Second, a PAPS regeneration
system would permit the PNPS as the sulfo donor and require only catalytic amounts of
PAP, significantly reducing the cost of synthesis. The listed price of PNPS in the Aldrich
catalog is 1300-fold less than PAPS. The immobilized enzyme format allowed us to use the
enzymes repeatedly, making the method amendable to a large scale synthesis, since scale-up
of immobilized enzyme columns is relatively simple.
Developing an effective approach to synthesize HS is also essential for understanding the
mechanism of its biosynthesis. Unlike the protein biosynthesis, polysaccharide biosynthesis
is not a template-driven process. Although the cDNAs encoding the HS biosynthetic
enzymes have been cloned, the genetic regulation mechanism for the synthesis of the HS
with defined biological functions is not fully understood. We now know that the unique and
often remote sequence features in substrate can influence the action of HS O-
sulfotransferases. Furthermore, whether additional factors or the formation of complexes of
biosynthetic enzymes takes part in controlling the structure of HS remains to be elucidated.
It is interesting to note that a complex of HS epimerase and 2-OST in vivo has been reported
(43). Our approach could provide a tool to answer these questions, since it is capable of
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generating a sufficient amount of HS product required for extensive structural biochemical
and biological analysis.
HS is believed to be present in block structures, consisting of highly sulfated and
nonsulfated domains (44), and the HS with the biological activities largely contain the
highly sulfated domains. We believe that the modifications in our system indeed happen in a
block fashion based on the following facts. First, the results of the disaccharide analysis
concluded that both 6-O-sulfation and 2-O-sulfation are carried out predominantly in the
sulfated region (Fig. 3 and TABLE ONE). Second, the enzymatically modified products
exhibit the anticipated biological functions, including the activation of FGF/FGF receptor
signaling (compounds 4a and 4b), carrying anticoagulant activity (compound 5), and
binding to herpes simplex virus glycoprotein D (compound 6). Because the HS carrying
these functions must contain the domain structures with the size larger than pentasaccharide
(5, 34, 39, 45), the synthetic products with the desired functions suggest that the
modifications indeed occur in a block fashion. Further investigation is needed to determine
whether the enzymatic modifications are identical to those in vivo. We note that the
GlcNAc6S unit is a common saccharide residue in the HS from natural sources; however, it
cannot be generated by 6-OST modification in vitro, suggesting the difference between in
vitro and in vivo synthesis (46).
In summary, we have described a method for enzymatic sulfation to prepare the HS with
three distinct biological activities. Unique sulfated saccharide sequences play a dominant
role in the function and specificity of HS/heparin. Our method demonstrates the feasibility
of using a collection of HS biosynthetic enzymes to synthesize HS/heparin with selected
biological activities. The synthetic scale with this method can be easily increased for large
scale synthesis, provided that both the enzymes and the sulfo donor are easily accessible.
Since the synthesis of HS polysaccharide is not a template-driven process, it is still not
possible to design an approach to synthesize a “sequence-pure” polysaccharide.
Nevertheless, the current method clearly demonstrates that HS/heparin having specific
biological activities can be synthesized by subjecting a backbone saccharide polymer to
different enzymatic modifications. This enzymatic selectivity is currently not accessible by
chemical sulfation approaches. Further improvement of this method will significantly aid the
exploration of new potential therapeutic applications for HS. In addition, enzymatic
synthesis of anticoagulant heparin could lead to a better anticoagulant drug by reducing its
side effects.
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FIGURE 1. Schematic synthesis of sulfated polysaccharides and PAPS regeneration system
A, the stepwise enzymatic synthesis of sulfated polysaccharides using HS sulfotransferases.
The description of intermediate polysaccharides is given under “Results.” Compounds 4a
and 4b were prepared by inverting the order of sulfation steps. 4a was prepared by
incubating compound 1 with 2-OST followed by 6-OST, whereas 4b was prepared by
incubating compound 1 with 6-OST followed by 2-OST. B, the reaction catalyzed by
arylsulfotransferase IV (AST-IV) to generate PAPS. R represents -H or -SO3.
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FIGURE 2. Activities of recycled immobilized sulfotransferases
The immobilized enzymes were utilized multiple cycles. The activities of the immobilized
enzymes after each were determined as described under “Experimental Procedures.” A total
of 10 cycles were conducted.
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FIGURE 3. RPIP-HPLC chromatograms of the disaccharide analysis of synthesized
polysaccharides
The synthesized polysaccharides were digested with a mixture of heparinases, including
heparin lyase I, II, III, and heparitinase IV. The resultant disaccharides were purified by
BioGel P-2 and resolved on RPIP-HPLC. A–E, the chromatogram of the disaccharide
analysis of compound 1, 2, 3, 4a, and 4b, respectively. The arrows indicate the eluted
positions of authentic disaccharide standards, where 1 represents ΔUA-GlcNAc, 2 represents
ΔUA-GlcNS, 3 represents ΔUA-GlcNS6S, 4 represents ΔUA2S-GlcNS, and 5 represents
ΔUA2S-GlcNS6S. *, the eluted position of ΔUA2SGlcNAc. Because we do not have this
disaccharide standard, we could not determine the quantity of ΔUA2S-GlcNAc.
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FIGURE 4. The effect of the synthesized polysaccharides on FGF-2-dependent BaF3 FGFR1c
cell proliferation
BaF3 FGFR1c cells were seeded in 96-well plates as described with 2 nM FGF2 for control
and 2 nM FGF2 plus a 1μg/ml concentration of the following compounds: heparin, 1, 2, 3,
4a, and 4b (A). B, dose-response curves of heparin, 4a, and 4b for their activities in
stimulating cell proliferation. Cells were cultured for 40 h, followed by incubating in the
media containing [3H]thymidine for 4 h. The cellular proliferation was determined by
[3H]thymidine incorporation into the DNA. Data are mean ± range of duplicates.
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TABLE THREE
Anti-factor Xa and antithrombin activities of synthesized polysaccharide intermediates
Sample Factor Xa inhibition (IC50)a Thrombin inhibition (IC50)a Binding to ATb
ng/ml ng/ml %
Heparinc 20 10 NDd
Heparan sulfatee >5000 >3000 ND
Arixtraf 58 >3000 ND
Compound 7 >2000 >3000 5
Compound 8 126 96 31
Compound 5 40 32 38
Compound 6 >2000 >2000 2
a
The procedures for measuring the activities of factor Xa and thrombin are described under “Experimental Procedures.”
b
3-O-[35S]sulfo compounds were used to determine their bindings to AT as described under “Experimental Procedures.” 3H-Labeled HS from
CHO cells was used as a negative control for the AT binding. About 0.3% of 3H-labeled HS bound to AT.
c




Heparan sulfate was isolated from bovine kidney.
f
Arixtra is the chemically synthesized antithrombin-binding pentasaccharide, which was obtained from a local pharmacy.
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TABLE FOUR









[3H]HS (from CHO cells) was prepared by metabolically labeling the cells with [3H]glucosamine.
b
3-OST-1- and 3-OST-3-modified HS were prepared by incubating [3H]HS with purified 3-OST-1 or 3-OST-3 enzymes.
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